Martin Holst Lange, Executive Vice President and Chief Scientific Officer, sold 12,000 Novo Nordisk B shares on November 4, 2026, at a price of DKK 285.00 per share, resulting in an aggregate transaction value of approximately DKK 3,420,000. The sale was reported to the company and published pursuant to Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company that develops treatments for diabetes, obesity, and other chronic diseases.
